Literature DB >> 25845035

Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority.

Nicoletta Riva1, Walter Ageno1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25845035      PMCID： PMC4385065          DOI： 10.2450/2015.0057-15

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  19 in total

1.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

2.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.

Authors:  T van der Hulle; J Kooiman; P L den Exter; O M Dekkers; F A Klok; M V Huisman
Journal:  J Thromb Haemost       Date:  2014       Impact factor: 5.824

Review 5.  Pulmonary embolism and deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Henri Bounameaux
Journal:  Lancet       Date:  2012-04-10       Impact factor: 79.321

6.  Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism.

Authors:  T van der Hulle; P L den Exter; J Kooiman; J J M van der Hoeven; M V Huisman; F A Klok
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

Review 7.  Pulmonary embolism: risk assessment and management.

Authors:  Stavros Konstantinides; Samuel Z Goldhaber
Journal:  Eur Heart J       Date:  2012-09-07       Impact factor: 29.983

8.  Apixaban for extended treatment of venous thromboembolism.

Authors:  Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Anthony Porcari; Gary E Raskob; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2012-12-08       Impact factor: 91.245

9.  Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism.

Authors:  Ramón Lecumberri; Ana Alfonso; David Jiménez; Carmen Fernández Capitán; Paolo Prandoni; Philip S Wells; Gemma Vidal; Giovanni Barillari; Manuel Monreal
Journal:  Thromb Haemost       Date:  2013-07-11       Impact factor: 5.249

10.  Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.

Authors:  Martin H Prins; Anthonie Wa Lensing; Rupert Bauersachs; Bonno van Bellen; Henri Bounameaux; Timothy A Brighton; Alexander T Cohen; Bruce L Davidson; Hervé Decousus; Gary E Raskob; Scott D Berkowitz; Philip S Wells
Journal:  Thromb J       Date:  2013-09-20
View more
  5 in total

1.  The use of novel oral anticoagulants: the debate continues!

Authors:  Massimo Franchini; Claudio Velati
Journal:  Blood Transfus       Date:  2015-04       Impact factor: 3.443

Review 2.  How we treat bleeding associated with direct oral anticoagulants.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giancarlo M Liumbruno; Massimo Franchini
Journal:  Blood Transfus       Date:  2016-01-19       Impact factor: 3.443

Review 3.  Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.

Authors:  Davide Imberti; Fulvio Pomero; Daniela Mastroiacovo
Journal:  Blood Transfus       Date:  2019-04-30       Impact factor: 3.443

Review 4.  The evolution of anticoagulant therapy.

Authors:  Massimo Franchini; Giancarlo M Liumbruno; Carlo Bonfanti; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2015-12-16       Impact factor: 3.443

5.  Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register.

Authors:  Gualtiero Palareti; Emilia Antonucci; Cristina Legnani; Daniela Mastroiacovo; Daniela Poli; Paolo Prandoni; Alberto Tosetto; Vittorio Pengo; Sophie Testa; Walter Ageno
Journal:  BMJ Open       Date:  2020-11-27       Impact factor: 2.692
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.